Movement Alert｜Roivant Sciences Ltd. Rises 28.66% in Pre-Market Trading, Core Pipeline Mosliciguat Achieves Positive Clinical Data in PH-ILD Study

Market Focus

Sep 08

On September 8, Roivant Sciences Ltd. rose 28.66% in pre-market trading, trading at $45.41/share, with turnover of $23.77 thousand.

On the news front, the company announced that its inhaled sGC activator Mosliciguat achieved positive results in the Phocus study evaluating the drug in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The data validated the drug's efficacy, offering a potential breakthrough for a condition that has long lacked effective treatment options. Additionally, the company disclosed the ongoing Phrontier Phase III trial, marking a significant step forward in Mosliciguat's clinical development and reinforcing its potential therapeutic position in this rare disease indication.

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on inflammation and immunology. Its core pipeline also includes brepocitinib, currently under FDA review, and IMVT-1402, a fully human monoclonal antibody targeting the neonatal Fc receptor.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/news/1174568525"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174568525\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174568525?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-08 18:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174568525","market":"us","top_or_hot":-1,"title":"Movement Alert｜Roivant Sciences Ltd. Rises 28.66% in Pre-Market Trading, Core Pipeline Mosliciguat Achieves Positive Clinical Data in PH-ILD Study","media":"Market Focus","content":"<p><p>On September 8, Roivant Sciences Ltd. rose 28.66% in pre-market trading, trading at $45.41/share, with turnover of $23.77 thousand.</p><p>On the news front, the company announced that its inhaled sGC activator Mosliciguat achieved positive results in the Phocus study evaluating the drug in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The data validated the drug's efficacy, offering a potential breakthrough for a condition that has long lacked effective treatment options. Additionally, the company disclosed the ongoing Phrontier Phase III trial, marking a significant step forward in Mosliciguat's clinical development and reinforcing its potential therapeutic position in this rare disease indication.</p><p>Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on inflammation and immunology. Its core pipeline also includes brepocitinib, currently under FDA review, and IMVT-1402, a fully human monoclonal antibody targeting the neonatal Fc receptor.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Roivant Sciences Ltd. Rises 28.66% in Pre-Market Trading, Core Pipeline Mosliciguat Achieves Positive Clinical Data in PH-ILD Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Roivant Sciences Ltd. Rises 28.66% in Pre-Market Trading, Core Pipeline Mosliciguat Achieves Positive Clinical Data in PH-ILD Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-08 18:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 8, Roivant Sciences Ltd. rose 28.66% in pre-market trading, trading at $45.41/share, with turnover of $23.77 thousand.</p><p>On the news front, the company announced that its inhaled sGC activator Mosliciguat achieved positive results in the Phocus study evaluating the drug in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The data validated the drug's efficacy, offering a potential breakthrough for a condition that has long lacked effective treatment options. Additionally, the company disclosed the ongoing Phrontier Phase III trial, marking a significant step forward in Mosliciguat's clinical development and reinforcing its potential therapeutic position in this rare disease indication.</p><p>Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on inflammation and immunology. Its core pipeline also includes brepocitinib, currently under FDA review, and IMVT-1402, a fully human monoclonal antibody targeting the neonatal Fc receptor.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"","article_id":"1174568525","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174568525","pubTimestamp":1788862009,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 8, Roivant Sciences Ltd. rose 28.66% in pre-market trading, trading at $45.41/share, with turnover of $23.77 thousand.On the news front, the company announced that its inhaled sGC...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd."},"translate_title":"走势警报|Roivant Sciences Ltd. 盘前交易上涨 28.66%，核心管线 Mosliciguat 在 PH-ILD 研究中取得积极临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1},"content_text":"On September 8, Roivant Sciences Ltd. rose 28.66% in pre-market trading, trading at $45.41/share, with turnover of $23.77 thousand.On the news front, the company announced that its inhaled sGC activator Mosliciguat achieved positive results in the Phocus study evaluating the drug in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The data validated the drug's efficacy, offering a potential breakthrough for a condition that has long lacked effective treatment options. Additionally, the company disclosed the ongoing Phrontier Phase III trial, marking a significant step forward in Mosliciguat's clinical development and reinforcing its potential therapeutic position in this rare disease indication.Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on inflammation and immunology. Its core pipeline also includes brepocitinib, currently under FDA review, and IMVT-1402, a fully human monoclonal antibody targeting the neonatal Fc receptor.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}